<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00305188</url>
  </required_header>
  <id_info>
    <org_study_id>EFC5505</org_study_id>
    <secondary_id>EUDRACT : 2005-002570-30</secondary_id>
    <nct_id>NCT00305188</nct_id>
  </id_info>
  <brief_title>Evaluation of the Efficacy of Xaliproden (SR57746A) in Preventing the Neurotoxicity of Oxaliplatin / 5FU/LV Chemotherapy.</brief_title>
  <official_title>A Multicenter, Randomized Double-blind Placebo Controlled Phase III Study of the Efficacy of Xaliproden in Preventing the Neurotoxicity of Oxaliplatin in First-line Treatment of Patients With Metastatic Colorectal Cancer Treated With Oxaliplatin / 5-FU/LV</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      Primary Objective : Compare the risk of occurrence of Grade3-4 cumulative peripheral sensory
      neuropathy (PSN) relative to cumulative dose of oxaliplatin between treatment group and
      placebo group.

      Main Secondary Objective : Compare the response rate (RR) between treatment group and placebo
      group in order to ensure that the efficacy of the chemotherapy is not compromised by the
      addition of xaliproden to the chemotherapeutic regimen.

      Other Secondary Objectives : study of the neurotoxicity parameters (Duration of
      oxaliplatin-induced PSN (G2,3,4); overall incidence of PSN during treatment; dose of onset of
      PSN ; incidence of dose-reduction and dose delay due to PSN; incidence of oxaliplatin
      treatment discontinuation due to PSN; change in Nerve Conduction Studies (NCS)) ; study of
      the safety profile (other than PSN) ; study of the chemotherapy efficacy (progression free
      survival, overall survival).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2005</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical evaluation of peripheral sensory neuropathy using the Oxaliplatin specific scale for dose adjustment</measure>
    <time_frame>Q2W during treatment, Q4W to Q12W during post-treatment follow-up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Main: response rate using RECIST criteria</measure>
    <time_frame>Q8W</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other: nerve conduction studies</measure>
    <time_frame>baseline, end of treatment with oxaliplatin, end of treatment with study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other: progression free survival and survival</measure>
    <time_frame>Q8W and study period</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">879</enrollment>
  <condition>Metastases</condition>
  <condition>Colorectal Neoplasms</condition>
  <condition>Colorectal Carcinoma</condition>
  <arm_group>
    <arm_group_label>Xaliproden (SR57746A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xaliproden (SR57746A)</intervention_name>
    <description>oral administration</description>
    <arm_group_label>Xaliproden (SR57746A)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>oral administration</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>IV administration</description>
    <arm_group_label>Xaliproden (SR57746A)</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-Fluorouracil</intervention_name>
    <description>IV administration</description>
    <arm_group_label>Xaliproden (SR57746A)</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>5-FU</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin</intervention_name>
    <description>IV administration</description>
    <arm_group_label>Xaliproden (SR57746A)</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>LV</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Main inclusion criteria :

          -  Histologically or cytologically-proven metastatic cancer of the colon or rectum.

          -  Metastatic disease not amenable to potentially curative treatment (eg: inoperable
             metastatic disease).

          -  Male or female aged &gt;18 years.

          -  WHO Performance Status (PS) : 0 or 1.

          -  Measurable disease.

          -  No prior chemotherapeutic regimen for metastatic disease.

          -  Disease-free interval from end of adjuvant therapy of at least 6 months (1 year if
             oxaliplatin was part of the adjuvant therapy).

          -  Prior radiotherapy is permitted if it was not administered to target lesions
             identified for this study - unless progression within the radiation portal is
             documented - and provided it has been completed at least 3 weeks before randomization.

          -  Signed written informed consent prior to study entry.

        Exclusion Criteria:

        Main exclusion criteria :

          -  Any condition or past medical history that contra-indicates treatment with oxaliplatin
             and 5-FU, as reported in approved labeling information.

          -  Received chemotherapeutic agents other than 5-FU, LV, Levamisole, irinotecan,
             capecitabine, oxaliplatin as part of adjuvant therapy.

          -  Peripheral neuropathy &gt;Grade 1.

          -  Concomitant treatments with drugs/ingredients reported to have a potential activity in
             preventing peripheral sensory neuropathy.

          -  Concurrent active cancer originating from a primary site other than colon or rectum.

          -  Presence of any symptom suggesting brain metastasis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Bridgewater</city>
        <state>New Jersey</state>
        <zip>08807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Macquarie Park</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Laval</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Porto Salvo</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Guildford Surrey</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Austria</country>
  </removed_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 20, 2006</study_first_submitted>
  <study_first_submitted_qc>March 20, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 21, 2006</study_first_posted>
  <disposition_first_submitted>April 6, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>April 6, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 4, 2016</disposition_first_posted>
  <last_update_submitted>April 6, 2016</last_update_submitted>
  <last_update_submitted_qc>April 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neurotoxicity syndromes</keyword>
  <keyword>Paresthesia</keyword>
  <keyword>Oxaliplatin</keyword>
  <keyword>Xaliproden</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Neurotoxicity Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

